dabrafenib mesylate

Known as: Dabrafenib Methanesulfonate 
The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
012320132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIMS The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients… (More)
  • figure 2
  • figure 3
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
IMPORTANCE Combined treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in only about 15% of patients… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma… (More)
  • table 1
  • table 2
  • table 4
  • table 3
  • figure 1
Is this relevant?
2015
2015
The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is… (More)
Is this relevant?
2014
2014
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. The population… (More)
Is this relevant?
Review
2014
Review
2014
Panniculitis is a rare complication of BRAF inhibitor therapy that is used to treat patients with BRAF-mutated metastatic… (More)
Is this relevant?
2013
2013
A phase I study was conducted to assess the metabolism and excretion of [(14)C]dabrafenib (GSK2118436; N-{3-[5-(2-amino-4… (More)
  • table 1
  • table 2
Is this relevant?
2013
2013
Hirnmetastasen treten bei der Mehrheit der Patienten mit metastasiertem Melanom auf und sind die häufigste Todesursache. Bis vor… (More)
Is this relevant?